Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Rheumatology’s Chronic Crisis

David S. Pisetsky, MD, PhD  |  Issue: August 2007  |  August 1, 2007

A troupe of puppeteers performs for attendees of the EULAR congress in Barcelona.

These trends are, of course, paradoxical because at present there is every reason for rheumatology to expand and prosper. With the increasing sophistication and complexity in patient care and the arrival of the baby boomers in droves at the doctors’ offices, the demand for rheumatology service will soar. Further, future improvements in care will likely involve more aggressive treatment approaches that will necessitate more visits and more intensive monitoring.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The past years have witnessed impressive treatment advances especially of inflammatory disease. Patient outcomes are continuously improving, with the development of new drugs and strategies making remission in RA, for example, a realistic goal. To explore fully the array of possibilities in RA alone afforded by existing agents, we would need a dramatic boost in investigators. To test the panoply of new agents in the pipeline, a veritable army would be needed. Similar issues pertain to the workforce needs to explore new treatments of osteoarthritis, osteoporosis, and the autoimmune diseases.

Nevertheless, despite the necessity to expand the field of rheumatology, many training programs can’t fund all of their approved positions and there is difficulty in recruiting new chiefs and leaders of once distinguished programs. In the setting of large academic medical centers, the training programs are often beleaguered as they are forced to downsize, hamstrung by financial models that are as harmful as they are baroque.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

My thirst quenched with the Vichy water, I was about to switch to cava to get a jump on the festivities of the evening ahead. With my colleagues engrossed in a serious powwow, however, I wanted to stay sharp and participate with them to come up with ideas for lessening our crises. I poured another glass of Vichy water.

Our conversation ebbed and flowed as we sent up trial balloon after trial balloon for finding solutions. Many of the suggestions were expected: Lobby Congress to increase National Institutes of Health spending; convince the medical school deans of the importance of rheumatology services; develop new financial models to take account of the downstream revenues rheumatologists generate.

While the expected ideas all have value, somehow none seemed particularly compelling or likely to succeed. Indeed, as the sun shone brilliant silver-gold in the afternoon sky over the white buildings of Barcelona, the world seemed a bit darker.

Crisis Solved?

In situations like this one, the simplest thing to say is, “Think outside the box.” Along with crisis, this is another phrase that I resist. Frankly, I abhor the idea that I inhabit a box and the phrase “think outside the box” is one of the most trite and overused of all exhortations for a group. Nevertheless, original thought is good and I will relate an outside-the-box idea that our stalwart group in the executive lounge advanced just prior to our expedition to the Parc Guell for EULAR’s 60th birthday party.

Page: 1 2 3 | Single Page
Share: 

Filed under:Education & Training Tagged with:PatientsResearch FundingTraining

Related Articles
    Lost and found

    The History of ACE Inhibitors in Scleroderma Renal Crisis

    February 16, 2021

    Scleroderma renal crisis is a true medical emergency in rheumatology, one that requires prompt diagnosis and treatment. Here, we review the historic introduction of the angiotensin-converting enzyme inhibitors in this context, and highlight management and key questions moving forward. Background Awareness of renal disease in scleroderma dates back many years. The revered physician William Osler…

    Minerals, Mud, Martinis, and Methylprednisone

    June 10, 2012

    How the practice of rheumatology differs in America and Europe.

    Avert Rheum’s Coming Crisis

    September 1, 2007

    We must build our foundation from within

    Cutaneous Lupus Tied to Risk for Coexisting Autoimmune Conditions

    May 10, 2018

    NEW YORK (Reuters Health)—Patients with cutaneous lupus erythematosus (CLE) should be monitored closely for other autoimmune conditions, researchers suggest. Dr. Benjamin Chong, Dr. Linda Hynan and Elaine Kunzler of the University of Texas Southwestern Medical Center in Dallas analyzed data from 129 adults in the UTSW Cutaneous Lupus Registry (mean age, 49; 79% women). Individuals…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences